PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials

PIK3CA mutations may predict response to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype has not been investigated. Patients with diverse cancers referred to the Clinical Center for Targeted Therapy were analyzed for PIK3CA and, if possible, KRAS mut...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Janku, Filip, Wheler, Jennifer J., Naing, Aung, Falchook, Gerald S., Hong, David S., Stepanek, Vanda M., Fu, Siqing, Piha-Paul, Sarina A., Lee, J. Jack, Luthra, Rajyalakshmi, Tsimberidou, Apostolia M., Kurzrock, Razelle
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3537862/
https://ncbi.nlm.nih.gov/pubmed/23066039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-1726
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares